Ra Capital Management, L.P. Acquires 59,880 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 59,880 shares of the stock in a transaction on Thursday, July 23rd. The shares were bought at an average price of $9.96 per share, for a total transaction of $596,404.80. Following the purchase, the director owned 17,242,483 shares in the company, valued at approximately $171,735,130.68. This trade represents a 0.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. bought 41,319 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.99 per share, with a total value of $412,776.81.
• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. purchased 120,582 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. acquired 6,552 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.

Artiva Biotherapeutics Trading Down 5.1%

NASDAQ ARTV opened at $10.00 on Thursday. The firm’s 50 day simple moving average is $8.92 and its 200 day simple moving average is $7.45. The firm has a market capitalization of $247.10 million, a price-to-earnings ratio of -2.82 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

ARTV has been the subject of a number of research analyst reports. HC Wainwright boosted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Wedbush increased their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the third quarter valued at about $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics during the first quarter worth about $131,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics during the fourth quarter worth about $91,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Artiva Biotherapeutics in the first quarter valued at approximately $139,000.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: RA Capital Management purchased an additional 41,319 ARTV shares at an average price of $9.99, investing approximately $413,000. This followed purchases of 59,880 shares on July 23, 84,124 shares on July 22, and 120,582 shares on July 21. The four transactions totaled roughly 306,000 shares and $3.0 million, increasing RA Capital’s ownership to more than 17.28 million shares. Continued insider accumulation can signal confidence in Artiva’s outlook and may provide a positive catalyst for the stock. Artiva Biotherapeutics director stock purchase report
• Positive Sentiment: Analyst coverage remains generally constructive. Artiva has an overall “Moderate Buy” rating and an average price target of $39, substantially above recent trading levels. Needham, Wedbush and Cantor Fitzgerald maintain bullish ratings, with Wedbush recently raising its target to $40. These targets reflect potential upside if Artiva’s off-the-shelf natural-killer-cell therapy pipeline advances successfully. Artiva Biotherapeutics analyst ratings
• Neutral Sentiment: Other institutional investors, including Bank of America, Jane Street, Qube Research & Technologies and Bridgeway Capital Management, have initiated or increased positions. However, the reported positions are relatively small and do not represent a major change in institutional ownership.
• Negative Sentiment: Artiva’s financial profile remains a risk. The company’s latest quarterly loss of $0.95 per share was worse than the $0.88 analyst consensus, and analysts expect a full-year loss of approximately $2.45 per share. Wall Street Zen and Weiss Ratings have issued sell-oriented views, underscoring concerns about ongoing cash needs, clinical execution and the absence of commercial revenue.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.